Park Medi World Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Healthcare Services | Market Cap: ₹11.9K Cr
Park Medi World expects a revenue growth of 24% for FY’27, targeting Rs. For FY'27, Park Medi World expects: - Revenue growth of 24% to Rs.
From Park Medi World's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹281
Market Cap
₹11.9K Cr
P/E Ratio
42.7
Revenue Rank
Margin Rank
How does Park Medi World rank in Healthcare Services?
Compare Park Medi World against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Park Medi World — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹460 Cr, net profit ₹77 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Park Medi World expects a revenue growth of 24% for FY’27, targeting Rs. 2,080 crores in revenue.
- →EBITDA is projected to grow by 25%, reaching Rs. 530 crores, and PAT is expected to grow by 32% to Rs. 360 crores.
- →ARPOB (Average Revenue Per Occupied Bed) growth guidance is 10%-12% annually for the next two years, driven by a shift toward advanced super-specialty treatments and inflation.
- →Bed capacity is planned to reach 4,740 by end of FY’27 and 5,740 by end of FY’28, with ongoing ramp-up in new facilities like Rudrapur and Panchkula.
- →Occupancy is expected to moderate due to new bed additions but mature hospitals will continue steady volume growth of 18%-20%.
- →Payer mix is shifting gradually from 77% government schemes to a future 70:30 split (government scheme: cash & TPA) over 12-18 months.
📈 Profitability & Margins
Rank 3- →For FY'27, Park Medi World expects:
- → - Revenue growth of 24% to Rs. 2,080 crores
- → - EBITDA growth of 25% to Rs. 530 crores, maintaining margins around 26.7%-27%
- → - PAT growth of 32% to Rs. 360 crores with PAT margin expanding to around 18.6%
- →Mature hospitals are expected to grow revenue steadily at 18-20%
- →Incremental economics remain attractive with return on capital currently at ~18%, and expected to improve by 150-200 bps over 12-18 months
- →New acquisitions like Rudrapur expected to ramp up revenues from Rs. 55-56 crores to Rs. 100 crores in first year with healthy EBITDA and PAT margins
- →ARPOB (Average Revenue per Occupied Bed) growth guided at 10-12% supported by shifting case mix towards high-end tertiary and quaternary care
- →EBITDA margins for hospitals with >60% occupancy expected at 30%-31%, and 15%-20% for sub 60% occupancy units
- →Management aims to maintain steady margin and profit growth despite bed additions and capacity expansion
🏗️ Capital Expenditure Plans
Yes- →Ongoing CAPEX and acquisition spend primarily focused on Rudrapur acquisition, Narela commissioning, and equipment upgrades across the network.
- →CAPEX per bed remains low at Rs.37 lakhs, the lowest among listed healthcare peers.
- →Total planned CAPEX for FY’27 and FY’28 is Rs.767 crores to add 2,130 beds, maintaining a blended CAPEX per bed of Rs.36 lakhs (includes acquisitions).
- →Additional CAPEX on Rudrapur expected to be around Rs.10-12 crores for equipment replacement and additions.
- →Adding 450 beds in Q3 FY’27, including 100 beds at Palam Vihar and 150 beds in Zirakpur.
- →Plan to increase total bed capacity to 4,740 by end FY’27 and to 5,740 by end FY’28.
- →Incremental CAPEX used to upgrade facilities, purchase high-end equipment, and support expansion with focus on high-end tertiary and quaternary care.
- →Fully funded growth plan through internal accruals and IPO proceeds, with minimal fresh debt.
💰 Fundraising & Capital Structure
Yes- →Park Medi World Limited is currently fully funded for its stated growth plan to reach 5,740 beds by March 2028 through internal accruals and IPO proceeds.
- →The company has indicated no need for material fresh debt for its expansion and acquisitions.
- →Regarding promoter equity, there is a regulatory mandate to reduce promoter holding to 75% by December 2028.
- →The company has a three-year timeline until December 2028 for this reduction and is evaluating opportunities for equity divestment aligned with its growth agenda.
- →No specific timeline or detailed plan for equity fundraising has been announced yet; management will share updates as clarity emerges.
📋 Order Book & Pipeline
No information- →There is no explicit mention of a current or expected order book or pending orders in the provided transcript.
- →The company focuses on bed capacity additions as part of its growth plan, with 1,490 beds added in calendar year 2026 and an expected total capacity of 4,740 beds by the end of FY’27, then reaching 5,740 beds by FY’28.
- →Acquisitions and extensions include the Rudrapur acquisition, Palam Vihar expansion, and a new acquisition in Zirakpur, totaling 450 beds for commissioning in late 2026.
- →CAPEX planned for FY’27 and FY’28 totals Rs.767 crore for 2,130 beds, maintaining a CAPEX per bed of Rs.36 lakhs on a blended basis.
- →No direct mention of order book or pending orders suggests the company is executing on identified expansion projects with no specific backlog disclosed.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Park Medi World Q1 FY27 results?
Park Medi World expects a revenue growth of 24% for FY’27, targeting Rs. For FY'27, Park Medi World expects: - Revenue growth of 24% to Rs.
What is Park Medi World share price analysis?
Park Medi World currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 42.7 with a market cap of ₹11,859 Cr. Investors should review the full earnings analysis for detailed insights.
Is Park Medi World planning capital expenditure?
Ongoing CAPEX and acquisition spend primarily focused on Rudrapur acquisition, Narela commissioning, and equipment upgrades across the network.
Keep Park Medi World on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.